68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer. - Wikidata - wikimedia - TriplyDB

68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer.

68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer.

http://www.wikidata.org/entity/Q52985406

about

Updates of prostate cancer staging: Prostate-specific membrane antigen Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients.Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer PSMA-PET/CT-Positive Paget Disease in a Patient with Newly Diagnosed Prostate Cancer: Imaging and Bone Biopsy Findings Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study.The accuracy of 68Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer.(68)Ga-PSMA-11 PET/CT: the rising star of nuclear medicine in prostate cancer imaging?PET imaging for lymph node dissection in prostate cancer.PSMA PET and Radionuclide Therapy in Prostate Cancer.Metal-Based PSMA Radioligands.Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer.68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.Comparison of 68Ga-PSMA-11 PET-CT with mpMRI for preoperative lymph node staging in patients with intermediate to high-risk prostate cancer.Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.Integration of CT urography improves diagnostic confidence of 68Ga-PSMA-11 PET/CT in prostate cancer patients.Salvage lymph node dissection after 68Ga-PSMA or 18F-FEC PET/CT for nodal recurrence in prostate cancer patients.Current status of theranostics in prostate cancer.99m Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer.Molecular imaging and fusion targeted biopsy of the prostate.68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review.Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour.[The role of PSMA PET-CT in patients with metastatic prostate cancer].Advances in prostate-specific membrane antigen PET of prostate cancer.The use of PET/CT in prostate cancer.[The role of PSMA PET-CT in patients with metastatic prostate cancer].Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer.Prostate Imaging-Reporting and Data System Version 2: Beyond Prostate Cancer Detection.[When is surgical treatment indicated in metastatic prostate cancer and what is the scientific rationale?]MRI and 11C Acetate PET/CT for Prediction of Regional Lymph Node Metastasis in Newly Diagnosed Prostate Cancer.PSMA Theranostics: Current Status and Future Directions.PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives.Prostate-Specific Membrane Antigen PET Imaging in Prostate Cancer: Opportunities and Challenges Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT Difference in Frequency and Distribution of Nodal Metastases Between Intermediate and High Risk Prostate Cancer Patients: Results of a Superextended Pelvic Lymph Node Dissection Keeping up with the prostate-specific membrane antigens (PSMAs): an introduction to a new class of positron emission tomography (PET) imaging agents Clinical implications of PET/CT in prostate cancer management

P2860

Q28079444-00350224-BDA4-419F-8155-939997A01B0A Q33841484-4E6DC2A5-F54D-4A00-BB0C-8CBBD618A6BF Q37709519-4DFAE6AD-2C61-4B15-973A-B376A6EA5A29 Q37726312-8C33CEB0-65EA-4856-944D-AFE670B54101 Q38665724-013048C4-6D50-4B42-A9E2-C79589A1051D Q38720852-44BD19DE-CF14-4592-ACDE-AD36CBDD635A Q38747415-C29EF8AA-C1EB-4237-A65C-906962746D4A Q38983526-F8F1AA2E-A38E-4FF7-86C6-6AF9BD14FDDB Q39003089-9548CCC7-B8E6-48DB-AB13-58D1EDC99180 Q39198527-0569910E-7C18-40AA-A90C-1DB7EFF26C97 Q42257970-127E95FC-B328-49E0-98FB-BBFCE462F76D Q46225464-D8D7006C-2A54-4A9C-A31B-163B5D9158C1 Q47097602-4E6991DA-0376-4888-8B69-D4F9E3C47D47 Q47107456-45136010-9E21-4EBA-BEE2-F00216C28BE6 Q47109640-FF7A7C21-1845-4C39-8F58-42B51C1EB01D Q47115390-7C0F1404-45C5-4B9C-A23F-D033C42F45A1 Q47241139-8DE06E79-1291-4CB6-BAFE-CA7D3576B670 Q47438555-505FA588-A0D9-41C0-BF26-1107BB4CC105 Q47608215-D03C268B-D931-4DEB-B1E7-2122833F2D91 Q48222301-1454712C-5B6D-4318-9514-98D55B803D2D Q48226517-1F5E9A43-493E-45D9-91A2-448E6B7CE2C5 Q48295687-FE475785-1CE1-4CE2-B9A1-B8CCB1BF73B9 Q49589359-D05A2876-B7A7-447F-8E52-E8593BA1766A Q49713199-A608F1D7-2978-4675-9110-F8FE296B1F5E Q49919217-FABB4D92-6A93-492E-98E3-13B459AF6906 Q49981290-87D99DC4-D481-4AE9-AE9D-E0457ADC7BE2 Q50034009-00AB8E78-20F5-4D98-AA4C-61EB0D6D09F7 Q52665654-E8D28091-68D9-4186-B993-F264C6DC8B47 Q52889384-7C5E074E-E9F6-464E-A5E2-7C3F4B78ECF1 Q55000240-63D1F293-8A34-496F-B379-29319CF53112 Q55023828-D034D98D-37F1-4FC1-B828-25425903EA95 Q55399763-E2A68CF8-57D3-4586-916C-A2AC615671AB Q57107208-BFB5369D-9924-420E-9E26-79AFB98E1BE8 Q57661498-A6774939-2266-4E2C-B4E2-A5F50306DDE2 Q58758865-AC4E0FDE-1784-43EB-A02C-FE841AEB74DF Q59130960-E3E23BDD-A053-44BE-BAFF-316E18269888 Q59137133-49ECD7EF-D980-4EF3-8C71-69472A9B2C55

P2860

68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer.

http://www.wikidata.org/entity/Q52985406

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

68Ga-PSMA Positron Emission To ...... Patients with Prostate Cancer.

@en

68Ga-PSMA Positron Emission To ...... Patients with Prostate Cancer.

@nl

type

label

68Ga-PSMA Positron Emission To ...... Patients with Prostate Cancer.

@en

68Ga-PSMA Positron Emission To ...... Patients with Prostate Cancer.

@nl

prefLabel

68Ga-PSMA Positron Emission To ...... Patients with Prostate Cancer.

@en

68Ga-PSMA Positron Emission To ...... Patients with Prostate Cancer.

@nl

P1433

Q52985406-E71F3395-C75A-4D91-AD28-79E28893680F

P1476

Q52985406-479E53FA-3057-4939-8A5B-9889388CD919

P2093

Q52985406-0DF261B8-0EA7-4530-B497-0D8262D38269

Q52985406-23F493E8-5287-484F-B217-A941E9766FF7

Q52985406-5C8AEA36-AA77-4D1F-9FE9-0854E04B5AED

Q52985406-66D38661-9F78-4D84-8088-49CF4B5C00AB

Q52985406-8D16B5F7-F233-4B00-83D7-159450168C60

Q52985406-9DE68447-A18F-48E5-9CE7-C3440B26BEEB

Q52985406-C78DEBD7-884C-4389-9F89-D765581427CF

Q52985406-D073BF39-9A90-47EC-A3C5-5AAB00AE04C0

Q52985406-F93C5D54-D37F-47EF-AFAA-15CF2645C99A

P304

Q52985406-87D2F627-E781-4A45-9816-8B9646FF0642

P31

Q52985406-E318594F-BFC8-4A61-AB91-6B7D0E6D4967

P356

Q52985406-636E85E5-BB59-420B-9895-921C31DA0A21

P407

Q52985406-B97D36C9-7F91-4394-B6BF-E23E89327B07

P433

Q52985406-0609A2F6-F5BA-4A50-B417-2740DA4F144B

P478

Q52985406-FB6BACA2-A792-41AC-97D3-3F672C85B92F

P50

Q52985406-9FE69F9E-3A9A-41CC-BFC4-5E22F84B68F9

P577

Q52985406-EEB98AE6-1027-4E0C-AC3C-41D55A8FCE66

P698

Q52985406-6D7AEB1C-63E9-49DD-B58F-24C484FD87D1

P921

Q52985406-2C0F1C4E-2700-4812-9AAE-007BBD59204C

P356

J.EURURO.2015.12.051

P1433

European Urology

P1476

68Ga-PSMA Positron Emission To ...... Patients with Prostate Cancer.

@en

P2093

Alexander Kretschmer

http://www.w3.org/2001/XMLSchema#string

Annika Herlemann

http://www.w3.org/2001/XMLSchema#string

Christian Gratzke

http://www.w3.org/2001/XMLSchema#string

Claudius Faber

http://www.w3.org/2001/XMLSchema#string

Franz-Josef Gildehaus

http://www.w3.org/2001/XMLSchema#string

Kolja M Thierfelder

http://www.w3.org/2001/XMLSchema#string

Peter Bartenstein

http://www.w3.org/2001/XMLSchema#string

Vera Wenter

http://www.w3.org/2001/XMLSchema#string

Wolfgang P Fendler

http://www.w3.org/2001/XMLSchema#string

P304

553-557

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EURURO.2015.12.051

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P50

Christian G Stief

P577

2016-01-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26810345

http://www.w3.org/2001/XMLSchema#string

P921